RECRUITING

Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.

Official Title

Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge

Quick Facts

Study Start:2024-12-01
Study Completion:2025-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05548205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female aged 18-100 years
  2. 2. Known history of type 1 or type 2 diabetes
  3. 3. Admitted to NYU Langone Hospital - Long Island between September 1st, 2022 and August 31st, 2023
  4. 4. New initiation of insulin therapy, including basal insulin regimen, basal-bolus insulin regimen, or mixed insulin regimen at the time of hospital discharge
  1. 1. Prior to admission use of home insulin therapy
  2. 2. Current use of systemic corticosteroids
  3. 3. Active pregnancy; as pregnancy requires different blood glucose targets, subjects known to be pregnant will be excluded from this study. Subjects will not be tested for pregnancy outside of testing performed in routine medical care; pregnancy will be determined by patient self-reporting. Females of childbearing potential will not be instructed to avoid pregnancy, however if they became pregnant during the study (detected by self-reporting), they will be withdrawn from the study.

Contacts and Locations

Study Contact

Stanislaw Klek
CONTACT
516-663-3511
Stanislaw.Klek@nyulangone.org
Michael Goldstein
CONTACT
516-663-3511
Michael.Goldstein@nyulangone.org

Principal Investigator

Stanislaw Klek
PRINCIPAL_INVESTIGATOR
NYU Langone Hospital - Long Island

Study Locations (Sites)

NYU Langone Hospital - Long Island
Mineola, New York, 11501
United States

Collaborators and Investigators

Sponsor: NYU Langone Health

  • Stanislaw Klek, PRINCIPAL_INVESTIGATOR, NYU Langone Hospital - Long Island

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-01
Study Completion Date2025-08-31

Study Record Updates

Study Start Date2024-12-01
Study Completion Date2025-08-31

Terms related to this study

Keywords Provided by Researchers

  • Continuous Glucose Monitoring (CGM)

Additional Relevant MeSH Terms

  • Diabetes